Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow

Oncology Reports

Volumn 9, Issue 6, 2002, Pages 1237-1244

  Yamashita, Kunihiro ^a   Iwasaki, Teruo ^a   Tsujimura, Tohru ^a   Sugihara, Ayako ^a   Yamada, Naoko ^a   Ueda, Haruyasu ^a   Okamura, Haruki ^a   Futani, Hiroyuki ^a   Maruo, Souji ^a   Terada, Nobuyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Bone; Interleukin 18; Multiple myeloma; NK cell

Indexed keywords

GAMMA INTERFERON; GANGLIOSIDE GM1; GANGLIOTETRAOSYLCERAMIDE; INTERLEUKIN 18; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BONE DISEASE; BONE MARROW; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; DISEASE MODEL; FEMALE; HUMAN; IMMUNOLOGY; IN VITRO STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MOUSE; MOUSE MUTANT; MULTIPLE MYELOMA; NATURAL KILLER CELL; OSTEOLYSIS; PATHOLOGY; PHENOTYPE; XENOGRAFT;

ANIMALS; BONE DISEASES; BONE MARROW; BONE RESORPTION; CELL DIVISION; DISEASE MODELS, ANIMAL; FEMALE; G(M1) GANGLIOSIDE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-18; KILLER CELLS, NATURAL; MICE; MICE, INBRED ICR; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; OSTEOLYSIS; PHENOTYPE; RECOMBINANT PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036835015     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.6.1237     Document Type: Article

References (43)

1. Mundy GR and Yoneda T: Facilitation and suppression of bone metastasis. Clin Orthop 312: 34-44, 1995.
2. Coleman RE: Skeletal complications of malignancy. Cancer 80 (Suppl 8): 1588-1594, 1997.
3. Roodman GD: Mechanisms of bone lesions in multiple myeloma. Cancer 80 (Suppl 8): 1557-1563, 1997.
4. Kanis JA and McCloskey EV: Bisphosphonates in multiple myeloma. Cancer 88 (Suppl 12): 3022-3032, 2000. (Pubitemid 30413186)
5. Guise TA and Mundy GR: Cancer and bone. Endocr Rev 19: 18-54, 1998. (Pubitemid 29122073)
6. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J and Alexandre C: Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88: 62-66, 1991.
7. Okamura H, Tsutsui H, Kashiwamura S-I, Yoshimoto T and Nakanishi K: A novel cytokine that augments both innate and acquired immunity. Adv Immunol 70: 281-312, 1998. (Pubitemid 128678839)
8. Lebel-Binay S, Berger A, Zinzindohoué F, Cugnenc P-H, Thiounn N, Fridman WH and Pages F: Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 11: 15-25, 2000. (Pubitemid 30145398)
9. Nakanishi K, Yoshimoto T, Tsutsui H and Okamura H: Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 19: 423-474, 2001. (Pubitemid 32368042)
10. Udagawa N, Horwood NJ, Elliott J, MacKay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ and Gillespie MT: Interleukin-18 (interferon γ-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation. J Exp Med 185: 1005-1012, 1997. (Pubitemid 27136793)
11. Horwood NJ, Udagawa N, Elliott J, Grail D, Okamura H, Kurimoto M, Dunn AR, Martin T and Gillespie: Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest 101: 595-603, 1998.
12. Yamada N, Niwa S, Tsujimura T, Iwasaki T, Sugihara A, Futani H, Hayashi S, Okamura H, Akedo H and Terada N: Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone 30: 901-908, 2002. (Pubitemid 34616021)
13. Iwasaki T, Yamashita K, Tsujimura T, Kashiwamura S-I, Tsutsui H, Kaisho T, Sugihara A, Yamada N, Mukai M, Yoneda T, Okamura H, Akedo H and Terada N: Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. J Immunother 25: (Suppl 1) S52-S60, 2002. (Pubitemid 34260758)
14. Nakata A, Tsujimura T, Sugihara A, Okamura H, Iwasaki T, Shinkai K, Iwata N, Kakishita E, Akedo H and Terada N: Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res 19: 4131-4138, 1999.
15. Micallef MJ, Yoshida K, Kawai S, Hanaya T, Kohno K, Arai S, Tanimoto T, Torigoe K, Fujii M, Ikeda M and Kurimoto M: In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 43: 361-367, 1997. (Pubitemid 27102222)
16. Fukumoto H, Nishio M, Nishio K, Heike Y, Arioka H, Kurokawa H, Ishida T, Fukuoka K, Nomoto T, Ohe Y and Saijo N: Interferon-γ-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Jpn J Cancer Res 88: 501-505, 1997. (Pubitemid 27267613)
17. Osaki T, Péron J-M, Cai Q, Okamura H, Robbins PD, Kurimoto M, Lotze MT and Tahara H: IFN-γ-inducing factor/IL-18 administration mediates IFN-γ- and IL-12-independent antitumor effects. J Immunol 160: 1742-1749, 1998. (Pubitemid 28106460)
18. Tan J, Crucian BE, Chang AE, Aruga E, Aruga A, Dovhey SE, Tanigawa K and Yu H: Interferon-γ-inducing factor elicits antitumor immunity in association with interferon-γ production. J Immunother 21: 48-55, 1998. (Pubitemid 28044836)
19. Heuer JG, Tucker-McClung C and Hock RA: Neuroblastoma cells expressing mature IL-18, but not proIL-18, induce a strong and immediate antitumor immune response. J Immunother 22: 324-335, 1999. (Pubitemid 29309965)
20. Kikuchi T, Akasaki Y, Joki T, Abe T, Kurimoto M and Ohno T: Antitumor activity of interleukin-18 on mouse glioma cells. J Immunother 23: 184-189, 2000. (Pubitemid 30165167)
21. Arai N, Akamatsu S, Arai S, Toshimori Y, Hanaya T, Tanimoto T, Ikeda M, Tomura M, Fujiwara H and Kurimoto M: Interleukin-18 in combination with IL-2 enhances natural killer cell activity without inducing large amounts of IFN-γ in vivo. J Interferon Cytokine Res 20: 217-224, 2000. (Pubitemid 30123751)
22. Hara S, Nagai H, Miyake H, Yamanaka K, Arakawa S, Ichihashi M, Kamidono S and Hara I: Secreted type of modified interleukin-18 gene transduced into mouse renal cell carcinoma cells induces systemic tumor immunity. J Urol 165: 2039-2043, 2001.
23. Yoshimura K, Hazama S, Iizuka N, Yoshino S, Yamamoto K, Muraguchi M, Ohmoto Y, Noma T and Oka M: Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the IgK leader sequence. Cancer Gene Ther 8: 9-16, 2001. (Pubitemid 32151892)
24. Yoshida Y, Tasaki K, Kimura M, Takenaga K, Yamamoto H, Yamaguchi T, Saisho H, Sakiyama S and Tagawa M: Antitumor effect of human pancreatic cancer cells transduced with cytokine genes which activate Thl helper T cells. Anticancer Res 18: 333-336, 1998.
25. Nagai H, Hara I, Horikawa T, Fujii M, Kurimoto M, Kamidono S and Ichihashi M: Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest 18: 206-213, 2000. (Pubitemid 30164150)
26. Huang Y-W, Richardson JA, Tong AW, Zhang B-Q, Stone MJ and Vitetta ES: Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res 53: 1392-1396, 1993. (Pubitemid 23097122)
27. Alsina M, Boyce B, Devlin RD, Anderson JL, Craig F, Mundy GR and Roodman GD: Development of an in vivo model of human multiple myeloma bone disease. Blood 87: 1495-1501, 1996. (Pubitemid 26056914)
28. Burk KH, Drewinko B, Trujillo JM and Aheam MJ: Establishment of a human plasma cell line in vitro. Cancer Res 38: 2508-2513, 1978. (Pubitemid 8390829)
29. Miwa K, Hashimoto H, Yatomi T, Nakamura N, Nagata S and Suda T: Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease. Int Immunol 11: 925-931, 1999. (Pubitemid 29276604)
30. Micallef MJ, Tanimoto T, Kohno K, Ikeda M, Ikegami H and Kurimoto M: Augmentation of in vitro interleukin 10 production after in vivo administration of interleukin 18 is activated macrophage-dependent and is probably not involved in the antitumor effects of interleukin 18. Anticancer Res 18: 4267-4274, 1998. (Pubitemid 29043644)
31. Ogura T, Ueda H, Hosohara K, Tsuji R, Nagata Y, Kashiwamura S-I and Okamura H: Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice. Blood 98: 2101-2107, 2001.
32. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M and Kurimoto M: Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 17: 3253-3258, 1997. (Pubitemid 27522278)
33. Nakamura S, Otani T, Okura R, Ijiri Y, Motoda R, Kurimoto M and Orita K: Expression and responsiveness of human interleukin-18 receptor (IL-18R) on hematopoietic cell lines. Leukemia 14: 1052-1059, 2000. (Pubitemid 30389511)
34. Bosma MJ and Carroll AM: The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 9: 323-350, 1991.
35. Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT and Tahara H: Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primary by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 163: 583-589, 1999. (Pubitemid 29328059)
36. Cao R, Farnebo J, Kurimoto M and Cao Y: Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J 13: 2195-2202, 1999.
37. Dao T, Ohashi K, Kayano T, Kurimoto M and Okamura H: Interferon-γ- inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 173: 230-235, 1996. (Pubitemid 26381401)
38. Tsutsui H, Nakanishi K, Matsui K, Higashino K, Okamura H, Miyazawa Y and Kaneda K: IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 157: 3967-3973, 1996. (Pubitemid 126449306)
39. Lauwerys BR, Renauld J-C and Houssiau FA: Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine 11: 822-830, 1999. (Pubitemid 29537530)
40. Hyodo Y, Matsui K, Hayashi N, Tsutsui H, Kashiwamura S-I, Yamauchi H, Hiroishi K, Takeda K, Tagawa Y, Iwakura Y, Kayagaki N, Kurimoto M, Okamura H, Hada T, Yagita H, Akira S, Nakanishi K and Higashino K: IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol 162: 1662-1668, 1999. (Pubitemid 29307043)
41. Son Y-I, Dallai RM, Mailliard RB, Egawa S, Jonak ZL and Lotze MT: Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells. Cancer Res 61: 884-888, 2001. (Pubitemid 32174396)
42. Kishida T, Asada H, Satoh E, Tanaka S, Shinya M, Hirai H, Iwai M, Tahara H, Imanishi J and Mazda O: In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther 8: 1234-1240, 2001. (Pubitemid 32780811)
43. Chikano S, Sawada K, Shimoyama T, Kashiwamura S-I, Sugihara A, Sekikawa K, Terada N, Nakanishi K and Okamura H: IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-γ dependent manner. Gut 47: 779-786, 2000. Technology